Table 1.
Cardiovascular risk markers demonstrating cardiovascular safety of CA dosed animals.
| Control (0.5% NaCMC) | C. auriculata (mg kg−1) | |||||
|---|---|---|---|---|---|---|
| HA | SFE | |||||
| 500 | 1000 | 250 | 500 | 1000 | ||
| Male | ||||||
| Homocysteine (μmol L−1) | 10.2 ± 1.52 | 9.5 ± 2.15 | 5.8 ± 1.51** | 7.7 ± 1.66 | 7.8 ± 3.10 | 5.5 ± 3.09** |
| CKMB (IU L−1) | 141.6 ± 26.65 | 143.8 ± 33.21 | 120.5 ± 20.0 | 135.7 ± 13.33 | 125.6 ± 31.55 | 120.4 ± 13.66 |
| Troponin I (ng mL−1) | 0.64 ± 0.03 | 0.67 ± 0.05 | 0.56 ± 0.10 | 0.48 ± 0.09 | 0.61 ± 0.08 | 0.55 ± 0.06 |
| Female | ||||||
| Homocysteine (μmol L−1) | 11.0 ± 2.52 | 10.0 ± 1.52 | 6.6 ± 1.74* | 6.9 ± 1.35 | 9.2 ± 1.85 | 6.5 ± 2.14* |
| CKMB (IU L−1) | 150.2 ± 30.27 | 138.9 ± 24.22 | 133.8 ± 15.88 | 145.5 ± 33.20 | 132.2 ± 30.9 | 135.5 ± 16.3 |
| Troponin I (ng mL−1) | 0.51 ± 0.10 | 0.47 ± 0.07 | 0.56 ± 0.09 | 0.55 ± 0.04 | 0.55 ± 0.03 | 0.67 ± 0.04 |
Data are expressed as mean ± SD, n = 6. *P < 0.05, **P < 0.01 significant decrease in homocysteine seen by 1000 mg kg−1 dose of CA-HA and CA-SFE.